Journal

The European Heart Journal – Cardio-Oncology (EHJ-CO) is an international, open-access, peer-reviewed
journal of the European Society of Cardiology dedicated to advancing knowledge in cardio-oncology. It complements existing ESC titles by fostering alignment and collaboration across the ESC Journal Family while maintaining a distinct editorial focus on cardio-oncology.

Aims & scope

This journal aims to advance the interdisciplinary field of cardio-oncology, focusing on the intersection of cardiovascular health and cancer care. We welcome high-quality research that advances understanding, prevention, and management of cardiovascular toxicity and cardiovascular disease in patients with cancer across the entire disease continuum. The journal particularly encourages rigorous clinical trials, as well as translational and mechanistic studies, that address key knowledge gaps in rapidly developing areas, including:

• Mechanisms of Cardiotoxicity: Basic and translational research elucidating mechanisms of cancer treatment-related cardiovascular toxicity, with special attention to novel oncological agents and combination therapies

• Risk Stratification and Early Detection: Integration of clinical, imaging, and novel biomarker data — supported by artificial intelligence — to refine risk stratification and enable early detection of cancer therapy-related cardiovascular toxicity.

• Cardio-Protection Strategies: Clinical and translational studies focused on strategies to prevent cardiovascular toxicity.

• Survivorship and Long-Term Care: Cardiovascular follow-up in cancer survivors, with emphasis on emerging therapies (immunotherapy, CAR-T cells, bone marrow transplantation) and refined risk stratification tools.

• Implementation Science: Multidisciplinary care models, health economics, and scalable cardiooncology services across diverse healthcare systems.

• Clinical Trial Integration: Incorporation of cardio-oncology endpoints into oncology and cardiovascular trials to generate actionable evidence for the optimal management of treatment related cardiotoxicity and cardiovascular disease in patients with cancer.

The candidate

The successful candidate will be:

• A highly regarded international expert in cardio-oncology

• Experienced as an author, reviewer, and in senior editorial roles

• Recognised for leadership, vision, and the ability to build strong collaborations

In addition, the candidate should demonstrate enthusiasm and dedication to advancing the field and to positioning EHJ-CO as a leading voice for the global cardiovascular health community. Applicants must be members of the ESC and, preferably, Fellows of the ESC (FESC). The ESC is committed to diversity, equity, and inclusion in all aspects of its activities and leadership appointments. We warmly encourage applications from candidates of all genders, nationalities, and backgrounds who bring varied perspectives to the role and share our mission to reduce the burden of cardiovascular disease.

How to apply

Enquiries and expressions of interest can be made, in confidence, by email: publications@escardio.org. A detailed brief with instructions on how to apply will be provided to those expressing interest in applying.

Application deadline: 31 January 2026